Gamida Cell (NASDAQ: GMDA)
Some price data may be temporarily unavailable.
Gamida Cell Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Gamida Cell Company Info
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.
News & Analysis
Why Gamida Cell Stock Is Soaring Today
The company released data from a late-stage clinical trial.
Why Is Everyone Talking About Gamida Cell Stock?
Early data for this company's natural killer cells is drawing lots of attention.
Valuation
Earnings Transcripts
Gamida Cell Ltd. (GMDA) Q2 2022 Earnings Call Transcript
GMDA earnings call for the period ending June 30, 2022.
Gamida Cell Ltd. (GMDA) Q1 2022 Earnings Call Transcript
GMDA earnings call for the period ending March 31, 2022.
Gamida Cell Ltd. (GMDA) Q4 2021 Earnings Call Transcript
GMDA earnings call for the period ending December 31, 2021.
Gamida Cell Ltd. (GMDA) Q3 2021 Earnings Call Transcript
GMDA earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.